NEWS

Davide Molho, DVM joins Viroclinics Biosciences as Chief Executive Officer

Viroclinics Biosciences B.V. (“Viroclinics”) today announced the appointment of life sciences industry veteran Davide Molho, DVM as the company’s new Chief Executive Officer. Dr. Molho succeeds Bob van Gemen, PhD who has served as the company’s CEO since 2011. This transition is part of a planned succession strategy. Dr. Molho’s appointment will take effect on 1 August 2020.

International partnership progresses UQ COVID-19 vaccine project

9 April 2020 The University of Queensland’s potential COVID-19 vaccine is entering an important new phase of testing with the live coronavirus to determine how effectively it induces protection against coronavirus infection. The UQ team will partner with the Dutch...

Viroclinics-DDL Diagnostic Laboratory Team to Support COVID-19 New Drug Investigations

Preceding weeks have made clear that COVID-19 continues to spread and is paralyzing the world. Times are unprecedented and show us how vulnerable we are and how we depend on each other. As a service organization – highly specialized in virology – we will commit ourselves to realign our resources, equipment and materials to new initiatives to test anti-virals, immune modulators and vaccines in the battle against COVID-19.

Summit Partners Announces Growth Equity Investment in Viroclinics

Global growth equity investor Summit Partners today announced a majority investment in Viroclinics Biosciences B.V., a leading specialized contract research organization (CRO) serving the global biopharmaceutical industry. The funding will be used to fuel continued expansion of Viroclinics’ services, capacity and international presence.

Viroclinics Xellerate provides better logistics support for the pharmaceutical, biotechnology, and medical device industries and gives us the opportunity to monitor the quality from the moment the sample is taken to the final test results. All personnel who are involved in the clinical trial are trained and all processes, temperature monitoring and assays are performed according to the ISO 15189 accredited quality system.

Logistic activities include preparation of virology sampling kits, on-site sampling handling instruction, courier transport, sample tracking and tracing (e.g. guaranteeing temperature controlled supply chain and online-sample timelines) , and management of sample processing labs. Viroclinics Xellerate support a smooth logistical flow of samples from all over the globe, and works together with a network of 36 processing laboratories in USA, Turkey, Mexico , Panama, Costa Rica, Argentina, Brazil , Peru ,Japan, South Korea, Singapore , China, Poland, Australia, India, South-Africa , Israel, Russia , Ukraine, Serbia, Colombia, UK, Germany, Spain, Saudi Arabia and Moldova.

Download Our Latest White Paper

 

↓